Combining Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) with Seattle Genetics’ antibody-therapy conjugate Adcetris (brentuximab vedotin) has been shown to be effective and safe in people with recurrent Hodgkin’s lymphoma (HL). Based on these ... Read more